Inactive Instrument

EQRx, Inc.

EQRX

US26886C1071

Biotechnology & Medical Research

EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P TMI Index

November 09, 2023 at 12:00 am EST

Latest news about EQRx, Inc.

Revolution Medicines Closes Acquisition of EQRx in All-Stock Deal	Nov. 09	MT
EQRx, Inc. Announces Board Resignations	Nov. 09	CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from NASDAQ Composite Index	Nov. 09	CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P Global BMI Index	Nov. 09	CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P Biotechnology Select Industry Index	Nov. 09	CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P TMI Index	Nov. 09	CI
Revolution Medicines, Inc. completed the acquisition of EQRx, Inc. from a group of shareholders.	Nov. 08	CI
Revolution Medicines, EQRx Stockholders Approve Merger	Nov. 08	MT
EQRx, Inc.(NasdaqGM:EQRX) dropped from NASDAQ Biotechnology Index	Nov. 08	CI
EQRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
EQRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Hansoh Pharmaceutical Terminates License Agreement With EQRx for Aumolertinib; Shares Slump 10%	23-08-07	MT
EQRx, Inc. Provides Written Notice to G1 Therapeutics of its Termination of the Exclusive License Agreement	23-08-03	CI
EQRx, Inc. Provides Written Notice to Hansoh Healthtech Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Company Ltd. of Its Termination of the Strategic Collaboration License Agreement	23-08-03	CI
Revolution Medicines Shares Rise After Accord to Acquire EQRx in All-Stock Deal	23-08-01	MT
Sector Update: Health Care Stocks Decline Premarket Tuesday	23-08-01	MT
Sector Update: Health Care	23-08-01	MT
Revolution Medicines Agrees to Acquire EQRx in All-Stock Deal	23-08-01	MT
Transcript : EQRx, Inc., Revolution Medicines, Inc. - M&A Call	23-08-01
Revolution Medicines Agrees to Acquire EQRx in All-Stock Deal	23-08-01	MT
Revolution Medicines, Inc. entered into a definitive agreement to acquire EQRx, Inc. from a group of shareholders for approximately $930 million.	23-07-31	CI
Goldman Sachs Lowers EQRx's Price Target to $3 From $5, Neutral Rating Kept	23-05-10	MT
CStone Pharmaceuticals to Regain Commercialization Rights to Cancer Treatments	23-05-08	MT
EQRx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Transcript : EQRx, Inc., Q1 2023 Earnings Call, May 08, 2023	23-05-08

EQRx, Inc. is a pharmaceutical company. The Company is engaged in developing medicines for some of the prevalent disease areas, including cancer and immune-inflammatory conditions. The Company brands include EQRx and Remaking Medicine. The Company's pipeline is comprised of approximately 10 programs, including both small molecules and biologics, with five clinical-stage programs, and several disclosed and undisclosed preclinical and drug engineering programs. Its clinical programs include Aumolertinib (EQ143), Lerociclib (EQ132), and Sugemalimab (EQ165). Aumolertinib (EQ143) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lerociclib (EQ132) is a novel and oral small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor. Sugemalimab (EQ165, also known as CS1001) is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research

EQRx, Inc.

Equities

EQRX

US26886C1071

Biotechnology & Medical Research

EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P TMI Index

Latest news about EQRx, Inc.

Chart EQRx, Inc.

Company Profile

Sector Other Biotechnology & Medical Research